{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:04:09Z","timestamp":1786122249197,"version":"build-2736575974"},"reference-count":57,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Cancer is fundamentally a genetic and epigenetic disease [...]<\/jats:p>","DOI":"10.3390\/ijms27167081","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T09:14:28Z","timestamp":1786094068000},"page":"7081","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Special Issue \u201cMolecular Research and Cellular Biology of Breast Cancer\u201d"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5178-9510","authenticated-orcid":false,"given":"Andrea","family":"Nicolini","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Pisa University, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.arcmed.2022.11.003","article-title":"Cancer Epigenetics: An Overview","volume":"53","year":"2022","journal-title":"Arch. Med. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.tig.2022.10.004","article-title":"Genetic and epigenetic defects of the RNA modification machinery in cancer","volume":"39","author":"Orsolic","year":"2023","journal-title":"Trends Genet."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/liv.14102","article-title":"Signaling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistance","volume":"39","author":"Fouassier","year":"2019","journal-title":"Liver Int."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e676","DOI":"10.1002\/mco2.676","article-title":"Renal cancer: Signaling pathways and advances in targeted therapies","volume":"5","author":"Jiang","year":"2024","journal-title":"MedComm"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.ccell.2025.05.003","article-title":"The pan-cancer proteome atlas, a mass spectrometry-based landscape for discovering tumor biology, biomarkers, and therapeutic targets","volume":"43","author":"Knol","year":"2025","journal-title":"Cancer Cell"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.3390\/ijms27052377","article-title":"Heterogeneity of Hormone Receptors and HER2 in Breast Cancer Cutaneous Metastases: An Institutional Experience","volume":"27","author":"Iozzo","year":"2026","journal-title":"Int. J. Mol. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/0190-9622(93)70173-Q","article-title":"Cutaneous metastases in patients with metastatic carcinoma: A retrospective study of 4020 patients","volume":"29","author":"Lookingbill","year":"1993","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jaad.2008.10.007","article-title":"Rates of cutaneous metastases from different internal malignancies: Experience from a Taiwanese medical center","volume":"60","author":"Hu","year":"2009","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/01.SMJ.0000053676.73249.E5","article-title":"Cutaneous metastasis: A meta-analysis of data","volume":"96","author":"Krathen","year":"2003","journal-title":"South. Med. J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"722","DOI":"10.5812\/ircmj.3611","article-title":"Expression of Testis Specific Genes TSGA10, TEX101 and ODF3 in Breast Cancer","volume":"14","author":"Dianatpour","year":"2012","journal-title":"Iran. Red Crescent Med. J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.2174\/1381612821666141211154707","article-title":"Cancer\/testis antigens trigger epithelial-mesenchymal transition and genesis of cancer stem-like cells","volume":"21","author":"Yang","year":"2015","journal-title":"Curr. Pharm. Des."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Ramchatesingh, B., Gantchev, J., Villarreal, A.M., Gill, R.P.K., Lambert, M., Sivachandran, S., Lefran\u00e7ois, P., and Litvinov, I.V. (2022). The Contributions of Cancer-Testis and Developmental Genes to the Pathogenesis of Keratinocyte Carcinomas. Cancers, 14.","DOI":"10.3390\/cancers14153630"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/cas.16433","article-title":"Evaluation of MAGE-A4 expression in breast cancer and its impact on prognosis","volume":"116","author":"Nakamura","year":"2025","journal-title":"Cancer Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"8958","DOI":"10.3390\/ijms26188958","article-title":"Investigating Germ Cell Transition Genes in Breast Cancer: Exploring the Genesis of Cancer Testis-Associated Markers","volume":"26","author":"Khodayari","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1038\/onc.2013.524","article-title":"Protein kinase C and cancer: What we know and what we do not","volume":"33","author":"Garg","year":"2014","journal-title":"Oncogene"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3390\/cancers3010531","article-title":"Protein kinase C: An attractive target for cancer therapy","volume":"3","author":"Marengo","year":"2011","journal-title":"Cancers"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.humpath.2007.11.001","article-title":"The overexpression and altered localization of the atypical protein kinase C lambda\/iota in breast cancer correlates with the pathologic type of these tumors","volume":"39","author":"Kojima","year":"2008","journal-title":"Hum. Pathol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"24108","DOI":"10.1073\/pnas.1906779116","article-title":"APKCi triggers basal extrusion of luminal mammary epithelial cells by tuning contractility and vinculin localization at cell junctions","volume":"116","author":"Villeneuve","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/CAD.0000000000000694","article-title":"Preclinical testing of 5-amino-1-((1R,2S,3S,4R)-2,3-dihydroxy-4-methylcyclopentyl)-1H-imidazole-4-carboxamide: A potent protein kinase C-\u03b9 inhibitor as a potential prostate carcinoma therapeutic","volume":"30","author":"Apostolatos","year":"2019","journal-title":"Anticancer Drugs"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Nowshin Oishee, N., Marzan, M., Olatunji, A.O., Khalid, K.M., Hasib Shourav, A., Noor, R.E., Kharitonova, A., Astalos, A.J., Leahy, J.W., and Acevedo-Duncan, M. (2025). PKC-\u03b9 Regulates an Oncogenic Positive Feedback Loop Between the MAPK\/JNK Signaling Pathway, c-Jun\/AP-1 and TNF-\u03b1 in Breast Cancer. Int. J. Mol. Sci., 26.","DOI":"10.20944\/preprints202506.1245.v1"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1080\/10255842.2023.2300681","article-title":"Revolutionizing Breast Cancer Care: AI-Enhanced Diagnosis and Patient History","volume":"28","author":"Fathima","year":"2025","journal-title":"Comput. Methods Biomech. Biomed. Eng."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10549-023-07038-3","article-title":"Frequent upregulation of HER2 protein in hormone-receptor-positive HER2-negative breast cancer after short-term neoadjuvant endocrine therapy","volume":"201","author":"Chaudhary","year":"2023","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Ji, W., Lou, Y., Jiang, W.G., Ruge, F., and Martin, T.A. (2025). Knockdown of Claudin-8 (CLDN8) Indicates a Link Between Breast Cancer Cell Sensitivity to Chemotherapeutics and Reveals a Potential Use of CLDN8 as a Molecular Diagnostic and Target for Therapy. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26115412"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Mull, M.L., Pratt, S.J.P., Thompson, K.N., Annis, D.A., Lee, R.M., Ju, J.A., Gilchrist, D.E., Stemberger, M.B., Boyman, L., and Lederer, W.J. (2025). Disruption of P2Y2 Signaling Promotes Breast Tumor Cell Dissemination by Reducing ATP-Dependent Calcium Elevation and Actin Localization to Cell Junctions. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26094286"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/S0022-3565(24)38983-9","article-title":"P2 purinergic receptors: Modulation of cell function and therapeutic potential","volume":"295","author":"Burnstock","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_26","first-page":"138","article-title":"P2Y2 receptor promotes the migration and invasion of breast cancer cells via EMT-related genes Snail and E-cadherin","volume":"39","author":"Qiu","year":"2018","journal-title":"Oncol. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"C411","DOI":"10.1152\/ajpcell.00100.2009","article-title":"The P2Y2 receptor mediates the epithelial injury response and cell migration","volume":"299","author":"Boucher","year":"2010","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s11302-020-09760-9","article-title":"Targeting the purinergic pathway in breast cancer and its therapeutic applications","volume":"17","author":"Kerkhoff","year":"2021","journal-title":"Purinergic Signal."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Stanciu, I.M., Orlov-Slavu, M.C., Parosanu, A.I., and Nitipir, C. (2025). Impact of Patient Profile on CDK4\/6 Inhibitor Therapy Outcomes: A Real-World Data Analysis. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26073357"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Faur, I.F., Dobrescu, A., Clim, I.A., Pasca, P., Burta, C., Tarta, C., Brebu, D., Neamtu, A.A., Braicu, V., and Duta, C. (2025). Prognostic Significance of Peripheral Blood Parameters as Predictor of Neoadjuvant Chemotherapy Response in Breast Cancer. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26062541"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ctrv.2016.03.002","article-title":"Targeting CDK4\/6 in patients with cancer","volume":"45","author":"Hamilton","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/ncponc0509","article-title":"Mechanisms of Disease: Understanding resistance to HER2-targeted therapy in human breast cancer","volume":"3","author":"Nahta","year":"2006","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"ref_33","first-page":"645","article-title":"Clinical outcomes of CDK4\/6 inhibitors in metastatic ER-positive HER2-negative breast cancer in a real-world setting","volume":"7","author":"Braunschweig","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Rasic, D., Stovgaard, E.I.S., Jylling, A.M.B., Hoang, T., Le Fevre, T., Salgado, R., Hartman, J., Rantalainen, M., and L\u00e6nkholm, A.V. (Virchows Arch., 2026). Level of estrogen receptor expression, histological grade, and computationally assessed stromal TILs on pre-treatment biopsies predict pathological complete response to neoadjuvant chemotherapy in ER-positive\/HER2-negative breast cancer, Virchows Arch., Epub ahead of print.","DOI":"10.1007\/s00428-026-04522-1"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"van den Ende, N.S., Nguyen, A.H., Jager, A., Kok, M., Debets, R., and van Deurzen, C.H.M. (2023). Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032969"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"7921","DOI":"10.1002\/cam4.4302","article-title":"Association of tumor-infiltrating lymphocytes before and after neoadjuvant chemotherapy with pathological complete response and prognosis in patients with breast cancer","volume":"10","author":"Hong","year":"2021","journal-title":"Cancer Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/bjc.2013.332","article-title":"Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer","volume":"109","author":"Stotz","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e047957","DOI":"10.1136\/bmjopen-2020-047957","article-title":"Role of neutrophil-to-lymphocyte ratio as a prognostic biomarker in patients with breast cancer receiving neoadjuvant chemotherapy: A meta-analysis","volume":"11","author":"Zhou","year":"2021","journal-title":"BMJ Open"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.breast.2018.12.014","article-title":"Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients","volume":"44","author":"Graziano","year":"2019","journal-title":"Breast"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Goidescu, I.G., Rotar, I.C., Nemeti, G., Staicu, A., Surcel, M., Cruciat, G., Mure\u0219an, D., Goidescu, C., and Eniu, D. (2025). Moderate-Low Risk Breast Cancer Gene Expression in a Romanian Population. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26115313"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s00432-020-03377-6","article-title":"Multigene panel testing for hereditary breast and ovarian cancer in the province of Ontario","volume":"147","author":"Mighton","year":"2021","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/gim.2015.166","article-title":"Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing","volume":"18","author":"Susswein","year":"2016","journal-title":"Genet. Med."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"D\u0142ugosz-Pokorska, A., Janecki, T., Janecka, A., and Gach-Janczak, K. (2025). Synergistic Effects of Oxaliplatin, 5-Fluorouracil, and Novel Synthetic Uracil Analog U-359 on Breast Cancer Cell Carcinogenesis. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26072964"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Rojas-Salazar, Y., G\u00f3mez-Monta\u00f1ez, E., Rojas-Salazar, J., de Anda-J\u00e1uregui, G., and Hern\u00e1ndez-Lemus, E. (2024). Potential Drug Synergy Through the ERBB2 Pathway in HER2+ Breast Tumors. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252312840"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s13046-024-03143-3","article-title":"The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody-drug conjugate-resistant HER2-overexpressing breast cancer","volume":"43","author":"Lee","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13058-019-1127-y","article-title":"Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer","volume":"21","author":"Kennedy","year":"2019","journal-title":"Breast Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Postigo-Corrales, F., Beltr\u00e1n-Videla, A., L\u00e1zaro-S\u00e1nchez, A.D., Hurtado, A.M., Conesa-Zamora, P., Arroyo, A.B., and Luengo-Gil, G. (2025). Docetaxel Resistance in Breast Cancer: Current Insights and Future Directions. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26157119"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e13840","DOI":"10.1016\/j.heliyon.2023.e13840","article-title":"Bufalin reverses ABCB1-mediated resistance to docetaxel in breast cancer","volume":"9","author":"Zhang","year":"2023","journal-title":"Heliyon"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"106573","DOI":"10.1016\/j.bioorg.2023.106573","article-title":"Synthesis and biological evaluation of atropisomeric tetrahydroisoquinolines overcoming docetaxel resistance in triple-negative human breast cancer cells","volume":"137","author":"Song","year":"2023","journal-title":"Bioorg. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13058-023-01665-w","article-title":"Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment","volume":"25","author":"Liu","year":"2023","journal-title":"Breast Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"116084","DOI":"10.1016\/j.biopha.2023.116084","article-title":"Programmed Co-delivery of tamoxifen and docetaxel using lipid-coated mesoporous silica nanoparticles for overcoming CYP3A4-mediated resistance in triple-negative breast cancer treatment","volume":"170","author":"Wang","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Ferrari, P., Schiavone, M.L., Scatena, C., and Nicolini, A. (2025). Molecular Mechanisms and Therapeutic Strategies to Overcome Resistance to Endocrine Therapy and CDK4\/6 Inhibitors in Advanced ER+\/HER2- Breast Cancer. Int. J. Mol. Sci., 26.","DOI":"10.20944\/preprints202503.1305.v1"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.biopha.2004.05.019","article-title":"Beta-interferon and interleukin-2 prolong more than three times the survival of 26 consecutive endocrine dependent breast cancer patients with distant metastases: An exploratory trial","volume":"59","author":"Nicolini","year":"2005","journal-title":"Biomed. Pharmacother."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.2174\/1389450117666160201114752","article-title":"Immunotherapy and Hormone-therapy in Metastatic Breast Cancer: A Review and an Update","volume":"17","author":"Nicolini","year":"2016","journal-title":"Curr. Drug Targets"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"941","DOI":"10.2174\/0929867325666180209124052","article-title":"The Use of Immunotherapy to Treat Metastatic Breast Cancer","volume":"26","author":"Nicolini","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s00109-020-01881-3","article-title":"A new immunotherapy schedule in addition to first-line hormone therapy for metastatic breast cancer patients in a state of clinical benefit during hormone therapy","volume":"98","author":"Nicolini","year":"2020","journal-title":"J. Mol. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"13","DOI":"10.20517\/2394-4722.2021.209","article-title":"Final results of a 2:1 control\u2013case observational study using interferon beta and interleukin-2, in addition to first-line hormone therapy, in estrogen receptor-positive, endocrine-responsive metastatic breast cancer patients","volume":"8","author":"Nicolini","year":"2022","journal-title":"J. Cancer Metastasis Treat."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/16\/7081\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T09:15:46Z","timestamp":1786094146000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/16\/7081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":57,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["ijms27167081"],"URL":"https:\/\/doi.org\/10.3390\/ijms27167081","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]}}}